Emily Olsen
The Peloton Guide will cost $495 and be available in the U.S. and Canada in early 2022.
Ellume began recalling the tests last month for giving false positive results.
The clinical trial results will be used to expand Viome’s mRNA platform, which in May received FDA breakthrough device designation for identifying early signs of oral and throat cancers.
The industrial giant plans to retain a stake of almost 20% in GE Healthcare.
Cue received emergency use authorization for its at-home COVID-19 test in March and went public in September.
The company said the latest round brings its total raise to $47 million.
The tool uses information about pain level, condition and current medication regimen to find an effective dose of opioids.
Nanox also completed the acquisition of USARAD Holdings and its affiliated company, MDWEB.
The plan, built with Trustmark Health Benefits, is centered on Teladoc’s primary care offering, recently made available to payers.
Also: Pediatric sleep app Huckleberry raises $12.5 million, and illumigyn, maker of a platform for remote gynecological imaging, brings in $33 million.